SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 162.88 |
| Enterprise Value ($M) | n/a |
| Book Value ($M) | 295.86 |
| Book Value / Share | 2.72 |
| Price / Book | n/a |
| NCAV ($M) | 146.76 |
| NCAV / Share | 1.35 |
| Price / NCAV | n/a |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | 0.00 |
| Return on Assets (ROA) | 0.00 |
| Return on Equity (ROE) | 0.00 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 2.54 |
| Current Ratio | 4.29 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 205.65 |
| Assets | 354.75 |
| Liabilities | 58.89 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13D/A | BT DE Investments Inc. | 30.00 | 15.74 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 156,997 | 486,599 | 32.26 | |
| 208,928 | 723,021 | 28.90 | |
| 444,097 | 1,216,280 | 36.51 | |
| 302,347 | 1,035,849 | 29.19 | |
| 222,819 | 743,759 | 29.96 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| NUVL – Nuvalent, Inc. | NVAX – Novavax, Inc. |
| NXTC – NextCure, Inc. | OLMA – Olema Pharmaceuticals, Inc. |
| OMGA – Omega Therapeutics, Inc. |
Financial data and stock pages provided by
Fintel.io